Sweden-based medical technology company SciBase Holding has said it is working with the US-based non-profit hospital Mayo Clinic to study pigmented lesion digital workflows with Nevisense.
Nevisense is an FDA-approved device that collects and analyses electrical measurements in the epidermis and dermis to provide data that is not available through any other method.
It combines artificial intelligence (AI) and Electrical Impedance Spectroscopy (EIS) technology to enhance diagnostic accuracy and improve skin health management.
The Nevisense platform also enables disease monitoring and early detection of melanoma and provides physicians with objective and actionable data at point-of-care.
SciBase said the device has been developed based on more than two decades of research from the Karolinska Institute and several years of clinical experience.
Mayo Clinic College of Medicine and Sciences professor of dermatology Alexander Meves said: “Melanoma is the deadliest form of skin cancer and accounts for the majority of skin cancer deaths because it can spread from the skin to other parts of the body where it becomes difficult to treat and can be fatal.
“However, if caught early, melanoma is almost 100% curable. For these reasons, we are looking forward to understanding how the Nevisense technology can help clinicians in the early detection of melanoma.”
SciBase CEO Pia Renaudin said: “We are proud to work with the Mayo Clinic and believe this pilot represents an opportunity for SciBase to continue to address an unmet medical need by expanding access to the Nevisense test to more US patients at-point-of-care, when it is critical and makes a profound impact on patient care.”
According to SciBase, Nevisense is the world’s first objective diagnostic support tool indicated for non-visual detection of severe cancer (malignant melanoma).
The platform provides a safe and painless method and allows physicians to make more informed decisions in difficult or borderline cases.
Building on its ability to enhance diagnostic accuracy, Nevisense is used as a diagnostic support tool for the early detection of cancers and the reduction of unnecessary biopsies.
The EIS functionality of Nevisense is intended for use on cutaneous lesions with one or more clinical or historical characteristics of melanoma.
Furthermore, the system is intended to be used for research purposes in general measurement of the electrical impedance of the skin, said SciBase.
